Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06602479 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

A Phase 2 study of Migraine, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
488
Enrollment target
20
Study locations

NCT06602479 is a Phase 2 study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 488 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06602479, a Phase 2 study of Migraine, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
488 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Conditions Studied

Migraine

Interventions

  • DRUG Placebo
  • DRUG MEDI0618

Study Locations (20)

Florida

  • Homestead Associates in Research, Inc. - Homestead
  • Florida Neurology - Lake Mary - Lake Mary
  • Flourish Research - Miami, LLC dba Flourish Research - Miami
  • BayCare Medical Group Neurology at St. Anthony's Hospital - St. Petersburg
  • Santos Research Center, Corp - Tampa - Tampa

Other

  • Brain-Soultherapy s.r.o. - Kladno
  • Clintrial s.r.o. - Prague
  • DADO Medical s.r.o. - Prague
  • Axon Clinical s.r.o. - Prague

Alabama

  • Flourish - Birmingham - Birmingham
  • Tennessee Valley Neurological Associates PC - Huntsville

California

  • The Neurology Center of Southern California - Carlsbad Office - La Jolla
  • Clinical Research Institute, LCC - Los Angeles

Kentucky

  • Norton Neuroscience Institute - Headache Clinic - Louisville

New York

  • Modern Migraine, MD - New York

Rhode Island

  • Velocity Clinical Research, Providence (East Greenwich) - East Greenwich

South Carolina

  • Palmetto Primary Care Physicians Division of Gastroenterology - Summerville - Summerville

Trial Details

FieldValue
Enrollment Target 488 participants
Start Date 2024-10-07
Est. Completion 2027-05-07
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06602479

The ClinicalTrials.gov registry entry for NCT06602479 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (38% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06602479 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Other, Alabama.

Frequently Asked Questions

What is clinical trial NCT06602479 about?

NCT06602479 is a clinical study titled "A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine". The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

What is the current status of trial NCT06602479?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 488 participants. The study started on 2024-10-07. Estimated completion is 2027-05-07.

What conditions does trial NCT06602479 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06602479?

The interventions under investigation include: Placebo (DRUG), MEDI0618 (DRUG).

Who is sponsoring clinical trial NCT06602479?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06602479 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.